Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment of advanced solid tumors.

T-1201 is a small molecular IV anti-cancer drug licensed from National Health Research Institutes in 2016. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug substance and drug products, it is anticipated to enter clinical development of T-1201 by early of 2021.